NurrOn entered into co-development agreement with HanAll Biopharma and Daewoong Pharmaceuticals to develop ATH-399A for Parkinson’s disease.
NurrOn received the award of the translational pipeline program 2022 for a Phase I trial of ATH-399A from Michael J. Fox Foundation.
https://www.michaeljfox.org/grant/development-nurr1-activator-novel-therapeutic-parkinsons-disease
Copyright © 2023 NurrOn Pharmaceuticals - All Rights Reserved.
Powered by GoDaddy Website Builder